Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis

References

• Diabetes; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed November 4, 2023.
   Google Scholar
• Saxena AR, Gorman DN, Esquejo RM, et al. Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nat Med. 2023;27(6):1079–1087. doi:10.1038/s41591-021-01391-w
   Web of Science ®Google Scholar
• Countries with highest number of diabetes cases unveiled; 2023. Available from: https://www.diabetes.co.uk/news/2023/jun/countries-with-highest-number-of-diabetes-cases-unveiled.html. Accessed November 4, 2023.
   Google Scholar
• Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int. 2020;11(3):165–223. doi:10.1007/s13340-020-00439-5
   PubMed Web of Science ®Google Scholar
• Morita Y, Murayama H, Odawara M, Bauer M. Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database. Diabetol Metab Syndr. 2023;11:1.
   Google Scholar
• Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2023;65(8):1251–1261. doi:10.1007/s00125-022-05715-4
   Web of Science ®Google Scholar
• Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes. Ann Int Med. 2020;173(4):278–287. doi:10.7326/M20-0864
   PubMed Web of Science ®Google Scholar
• Griffith DA, Edmonds DJ, Fortin JP, et al. A small-molecule oral agonist of the human glucagon-like peptide-1 receptor. J Med Chem. 2022;65(12):8208–8226. doi:10.1021/acs.jmedchem.1c01856
   PubMed Web of Science ®Google Scholar
• Aspnes GE, Bagley SW, Coffey SB, et al. 6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor. Bioorg Med Chem Lett. 2023;94. doi:10.1016/j.bmcl.2023.129454
   PubMed Web of Science ®Google Scholar
• Rahman A, Alqaisi S, Saith SE, Alzakhari R, Levy R. The impact of glucagon-like peptide-1 receptor agonist on the cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis and systematic review. Cardiol Res. 2023;14(4):250–260. doi:10.14740/cr1523
   PubMed Web of Science ®Google Scholar
• Saxena AR, Frias JP, Brown LS, et al. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2023;6(5):e2314493–e2314493. doi:10.1001/jamanetworkopen.2023.14493
   PubMed Web of Science ®Google Scholar
• Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403–412. doi:10.2147/DMSO.S141235
   PubMed Web of Science ®Google Scholar
• Saxena AR, Frias JP, Gorman DN, et al. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes. Diabetes Obes Metab. 2023;25(10):2805–2814. doi:10.1111/dom.15168
   PubMed Web of Science ®Google Scholar
• Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318(15):1460–1470. doi:10.1001/jama.2017.14752
   PubMed Web of Science ®Google Scholar
• Chen L, Yun Y, Guo S, et al. Discovery of novel 5,6-dihydro-1,2,4-triazine derivatives as efficacious glucagon-like peptide-1 receptor agonists. J Med Chem. 2023;66(12):7988–8010. doi:10.1021/acs.jmedchem.3c00320
   PubMed Web of Science ®Google Scholar
• Ono R, Furihata K, Ichikawa Y, et al. A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron PF −06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus. Diabetes Obes Metab. 2023;25(3):805. doi:10.1111/dom.14928
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;88:372.
   Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;2019:366.
   Google Scholar
• Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-The-art. Mol Metab. 2021;46:101102.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30. doi:10.1016/j.cmet.2016.06.009
   PubMed Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009
   PubMed Web of Science ®Google Scholar
• Shankar SS, Vella A, Raymond RH, et al. Standardized mixed-meal tolerance and arginine stimulation tests provide reproducible and complementary measures of β-cell function: results from the foundation for the national institutes of health biomarkers consortium investigative series. Diabetes Care. 2016;39(9):1602–1613. doi:10.2337/dc15-0931
   PubMed Web of Science ®Google Scholar
• Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven Phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15(1):42–54. doi:10.1111/j.1463-1326.2012.01673.x
   PubMed Web of Science ®Google Scholar
• Ahrén B, Atkin SL, Charpentier G, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018;20(9):2210–2219. doi:10.1111/dom.13353
   PubMed Web of Science ®Google Scholar
• Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392–406. doi:10.1016/S2213-8587(20)30074-7
   PubMed Web of Science ®Google Scholar
• Niman S, Hardy J, Goldfaden RF, et al. A review on the efficacy and safety of oral semaglutide. Drugs R D. 2021;21(2):133–148. doi:10.1007/s40268-021-00341-8
   PubMed Web of Science ®Google Scholar
• Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388. doi:10.1210/clinem/dgaa863
   PubMed Web of Science ®Google Scholar
• Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352–1355. doi:10.2337/dc19-1892
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–2193. doi:10.1016/S0140-6736(18)32260-8
   PubMed Web of Science ®Google Scholar
• Gaborit B, Julla JB, Besbes S, et al. Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the angiosafe type 2 diabetes study. J Clin Endocrinol Metab. 2020;105(4):E1549–60. doi:10.1210/clinem/dgz069
   Web of Science ®Google Scholar
• Pang B, Zhou H, Kuang H. The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy. Peptides. 2018;100:123–126. doi:10.1016/j.peptides.2017.08.003
   PubMed Web of Science ®Google Scholar
• Cai X, Li J, Wang M, et al. GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1/2-HDAC6 signaling pathway. Int J Med Sci. 2017;14(12):1203–1212. doi:10.7150/ijms.20962
   PubMed Web of Science ®Google Scholar